Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Current Liabilities: 2017-2025

Historic Total Current Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $25.6 million.

  • Aclaris Therapeutics' Total Current Liabilities rose 36.22% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 36.22%. This contributed to the annual value of $31.6 million for FY2024, which is 2.08% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Total Current Liabilities of $25.6 million as of Q3 2025, which was down 4.50% from $26.8 million recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Total Current Liabilities peaked at $31.6 million during Q4 2024, and registered a low of $14.5 million during Q1 2021.
  • Moreover, its 3-year median value for Total Current Liabilities was $22.8 million (2023), whereas its average is $23.6 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Total Current Liabilities plummeted by 31.31% in 2024, and later surged by 71.15% in 2025.
  • Aclaris Therapeutics' Total Current Liabilities (Quarterly) stood at $22.9 million in 2021, then fell by 4.33% to $21.9 million in 2022, then skyrocketed by 41.09% to $31.0 million in 2023, then rose by 2.08% to $31.6 million in 2024, then skyrocketed by 36.22% to $25.6 million in 2025.
  • Its last three reported values are $25.6 million in Q3 2025, $26.8 million for Q2 2025, and $21.5 million during Q1 2025.